A method for determining sulfadiazine dosing regimens in aquatic animals at different temperatures
By studying the dosing scheme of sulfadiazine on spotted fork tail oxidine at different temperatures, the pharmacokinetic parameters were measured, and personalized dosing schemes were formulated, which solved the problem of sulfadiazine absorption and metabolic characteristics of aquatic animals under temperature changes, and improved the treatment Effects and medication safety reduce economic losses.
Patent Information
- Application Number
- CN202210163032.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-22
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-02-22
AI Technical Summary
Changes in the absorption, metabolism and excretion characteristics of sulfadiazine in aquatic animals at different temperatures have led to poor effectiveness in the existing dosing regimen and it is difficult to effectively treat diseases caused by Edwardia, resulting in economic losses.
MIC value, oral perfusion and intravenous administration were determined by micro-dilution of spotted fork oxidazine at 18°C and 24°C, tissue samples were collected, drug residues were measured, pharmacokinetic parameters were calculated, and personalized administration was formulated. plan.
It improves the therapeutic effect of sulfadiazine, provides a more scientific drug use plan, improves drug use efficiency and safety, and reduces the economic losses of bacterial diseases to aquaculture.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure BDA0003514778540000021
Abstract
Description
Technical Field
[0001] The invention relates to the field of aquatic drug efficacy, and in particular to a method for determining a sulfadiazine dosing regimen in aquatic animals at different temperatures. Background Art
[0002] Fish are cold-blooded animals, and their body temperature changes with the ambient temperature. Temperature can change the physiological parameters of fish, such as heart rate, respiratory rate, cardiac output, excretion rate, and activity of metabolic enzymes, thus directly or indirectly affecting the absorption, metabolism, distribution, and excretion of fishery drugs, thereby changing the kinetic parameters of fishery drugs and affecting their effects, so the dosing regimen needs to be changed.
[0003] Edwardsiella ictaluri belongs to the genus Edwardsiella of the family Enterobacteriaceae. It is a Gram-negative short rod and an important pathogen of channel catfish. In recent years, channel catfish farming has developed rapidly in my country, especially in provinces such as Hubei, Hunan and Sichuan. With the continuous expansion of farming scale and the increase in farming density, the harm of the disease is becoming more and more serious. Edwardsiella ictaluri is an important pathogen of channel catfish, with rapid onset and high mortality rate, resulting in a large amount of economic losses. Sulfadiazine has good biofilm penetration ability and still has a good therapeutic effect on this bacterium.
[0004] In order to determine the dosing regimen of sulfadiazine at different temperatures, the present invention aims to invent a method for determining the dosing regimen of sulfadiazine in aquatic animals at different temperatures. Summary of the invention
[0005] The purpose of the present invention is to provide a method for determining a sulfadiazine dosing regimen in aquatic animals at different temperatures to solve the problems existing in the above-mentioned prior art. The method for determining a sulfadiazine dosing regimen in aquatic animals at different temperatures of the present invention can improve the therapeutic effect of sulfadiazine.
[0006] To achieve the above object, the present invention provides a method for determining the dosage regimen of sulfadiazine in aquatic animals at different temperatures, comprising the following steps:
[0007] Step 1: Isolate Edwardsiella ictaluri from clinically diseased fish and determine the MIC value of sulfadiazine against Edwardsiella ictaluri by microdilution method;
[0008] Step 2: administer the drug orally to channel catfish at 18°C and 24°C respectively, and collect tissue samples after administration;
[0009] Step 3: administer a single intravenous dose to channel catfish and collect tissue samples after administration;
[0010] Step 4: respectively determining the residual amount of sulfadiazine in the tissue samples collected in step 2 and step 3;
[0011] Step 5: Calculate pharmacokinetic parameters, including area under the concentration-time curve, absorption rate constant, elimination rate constant, and apparent distribution volume;
[0012] Step 6: Determine the dosage regimen of sulfadiazine according to calculation formula 1;
[0013] The calculation formula 1 is:
[0014]
[0015] In the calculation formula 1, Dose is the drug dose; Cmin is the steady-state concentration of sulfadiazine in fish, which is determined according to MIC; Vd is the apparent distribution volume; Ka is the absorption rate constant; K is the elimination rate constant; F is the bioavailability; Δ is the dosing interval;
[0016] The calculation formula 2 of the bioavailability is:
[0017]
[0018] In the calculation formula 2: AUCoral is the area under the curve for oral administration; AUCiv is the area under the curve for intravenous administration; Doseiv is the intravenous dose; Doseoral is the oral dose.
[0019] Furthermore, in step 2 and step 3, the sampling time points are 0.083, 0.167, 0.5, 1, 2, 8, 16, 24, 48 and 72 h after administration.
[0020] Furthermore, in step 2 and step 3, the tissue samples are blood, muscle + skin, liver, kidney and gill.
[0021] Furthermore, in step 4, the residual amount of sulfadiazine is determined by high performance liquid chromatography.
[0022] The present invention discloses the following technical effects:
[0023] The method of the present invention can obtain the pharmacokinetic parameters of sulfadiazine at different temperatures, and formulate dosing plans at different ambient temperatures based on the pharmacodynamic data of Edwardsiella ictaluri, thereby providing technical support for clinical drug use in aquaculture, more scientifically improving drug use efficiency and drug safety, and reducing the huge economic losses caused by bacterial diseases to aquaculture. DETAILED DESCRIPTION
[0024] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0025] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0026] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0027] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0028] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0029] Example 1
[0030] 1. Experimental Animals
[0031] 150 healthy channel catfish (average weight 420.4±37.2g) were purchased from the experimental base of Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences. The experimental water was continuously aerated by an aerator pump to maintain the dissolved oxygen in the water greater than 4.8mg / L, the pH was 7.2-7.8, and the temperature was divided into two groups, 18±0.5℃ and 24±0.5℃ respectively. Before the experiment, the fish were placed in a glass aquarium for one week.
[0032] 2. Drugs and reagents
[0033] Drugs: Sulfadiazine powder was purchased from Hubei Aibo Technology Co., Ltd., with a content greater than 98%; standard sulfadiazine was purchased from Dr. Ehrenstorfer Company in Germany, with a content greater than 99%.
[0034] Reagents:
[0035] Anhydrous magnesium sulfate, sodium chloride and disodium hydrogen phosphate were purchased from Shanghai Sinopharm Group with analytical grade; neutral alumina powder and C18 powder were purchased from Tianjin Bonaiger Technology Co., Ltd.; acetonitrile, water and formic acid (purity 88%) were all chromatographically pure and purchased from JTBaker, USA.
[0036] 3. Main instruments
[0037] High-speed refrigerated centrifuge (20PR2520, Hitachi, Japan); electronic balance (Mettler-TOLEDOAE-240, Mettler-Toledo); nitrogen blowdown instrument (KD200, Gongyi Yuhua Co., Ltd.); vortex mixer (Shanghai Kanghua Biochemical Instrument Manufacturing Co., Ltd.); high performance liquid chromatography-tandem mass spectrometry (Thermo TSQ Quantum Access MAX, Thermo Corporation, USA).
[0038] 4. Test sampling
[0039] The sampling time points were 0.083, 0.167, 0.5, 1, 2, 8, 16, 24, 48 and 72 h after administration, and 5 fish were collected at each time point, and blood, muscle + skin, liver, kidney and gill were collected.
[0040] 5. Determination of sulfadiazine dosing regimen in aquatic animals at different temperatures
[0041] Step 1: Isolate Edwardsiella ictaluri from clinically ill fish and determine the MIC value of sulfadiazine against Edwardsiella ictaluri by microdilution method. First, the bacteria were revived and the sulfadiazine standard solution was diluted to various concentrations. The two were added to a 96-well plate at a volume ratio of 1:1. The final concentration of bacteria in the 96-well plate was 5×10 5 CFU / mL, and complete the mixed bacteria in 96 microplates within 15 minutes, and set up positive and negative control groups. Then put it in a constant temperature incubator and culture it at 28℃ for 24 hours. The minimum clear well drug concentration is the MIC value.
[0042] Step 2: At an ambient temperature of 18°C, a single oral administration of 50 mg / kg BW was performed to channel catfish, and samples were collected according to "4. Test Sampling" after the administration.
[0043] Step 3: At an ambient temperature of 24°C, a single oral administration of 50 mg / kg BW was performed to channel catfish, and samples were collected according to "4. Test Sampling" after the administration.
[0044] Step 4: At an ambient temperature of 18 and 24°C, a single intravenous administration of 5 mg / kg BW was performed to channel catfish, and samples were collected according to "4. Test Sampling" after administration.
[0045] Step 5: The collected tissues were subjected to sample pretreatment and then to HPLC analysis. The results are shown in Tables 1 and 2.
[0046] Sample pretreatment: Weigh 1mL or 1g of aquatic product sample, add 1.5g of anhydrous sodium sulfate and 0.75g of sodium chloride, add 5mL of pure acetonitrile as extractant, vortex, centrifuge at 4500g for 5min, and take the supernatant. Then extract again according to the above procedure and combine the supernatants. Add 150mg of dispersed solid phase extraction reagent neutral alumina powder and C18 powder (1:1) to the supernatant, vortex and centrifuge at 4000g for 2min, transfer the supernatant to another centrifuge tube, blow dry with nitrogen in a 45℃ water bath, and then add a mixture of acetonitrile and water with a volume ratio of 15% to re-dissolve, filter through a 0.22μm organic filter membrane, and detect the filtrate by high performance liquid chromatography.
[0047] HPLC detection of sulfadiazine residues in samples:
[0048] The chromatographic column is a C18 column, 100 mm × 2.1 mm, with a particle size of 1.7 μm; the flow rate is 0.5 ml / min, and the column temperature is 30°C. The mobile phase A is acetonitrile (containing 15% methanol), and B is water (containing 0.1% formic acid).
[0049] Isocratic elution: A:B = 20:80
[0050] The detection wavelength was 280 nm.
[0051] Step 6: Evaluate pharmacokinetic parameters at different temperatures.
[0052] Software 3P97 was used to calculate pharmacokinetic parameters, including area under the concentration-time curve, absorption half-life, elimination half-life, peak time, peak concentration, apparent distribution volume and clearance.
[0053] Step 7: Determine the dosage regimen of sulfadiazine according to the formula based on the changes in pharmacokinetic parameters at different temperatures.
[0054] The formula used is:
[0055]
[0056] Dose is the drug dose; Cmin is the steady-state concentration of sulfadiazine in channel catfish, determined according to MIC; Vd is the apparent distribution volume; Ka is the absorption rate constant; K is the elimination rate constant; F is the bioavailability; Δ is the dosing interval.
[0057] The calculation formula of bioavailability is:
[0058]
[0059] AUCoral is the area under the curve for oral administration; AUCiv is the area under the curve for intravenous administration; Doseiv is the intravenous dose; Doseoral is the oral dose.
[0060] Table 1 Concentrations of sulfadiazine in plasma and tissues of channel catfish at 18°C (μg / kg, n=5)
[0061]
[0062] Table 2 Concentrations of sulfadiazine in plasma and tissues of channel catfish at 24°C (μg / kg, n=5)
[0063]
[0064]
[0065] In the present invention, the detection limit of sulfadiazine in plasma, gill, muscle + skin, liver and kidney was 7.0 μg / L (μg / kg) and the quantification limit was 10 μg / L (μg / kg). In order to accurately determine the samples, the accuracy and precision of the method of the present invention were investigated (Table 3). The recovery of sulfadiazine at high, medium and low concentrations was estimated to be 83.5%-92.1%, respectively. The intra-day and inter-day coefficients of variation (CV%) were less than 10%.
[0066] Table 3 Accuracy and precision of sulfadiazine and its metabolites in liver, kidney and muscle + skin of channel catfish
[0067]
[0068] 6. Calculation of pharmacokinetic parameters (see Table 4)
[0069] The classical compartments were used to fit the pharmacokinetic parameters in plasma and tissues.
[0070] Compartments were determined by the Akaike information criterion.
[0071] The pharmacokinetic parameters are calculated as shown in Table 4:
[0072] Table 4 Pharmacokinetic parameters of sulfadiazine in plasma, kidney, liver, muscle + skin and plasma of channel catfish at different temperatures
[0073]
[0074]
[0075] Note: AUC, area under the concentration-time curve; Ka_HL, absorption half-life; K_HL, elimination half-life; Ka, absorption rate constant; K, elimination rate constant; Tmax, time to peak; Cmax, peak concentration; Vd, apparent volume of distribution; Cl, systemic clearance; NA, not available.
[0076] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for determining the dosage regimen of sulfadiazine in aquatic animals at different temperatures, characterized in that: The following steps are involved: Step 1: Isolate Edwardsiella ictaluri from clinically diseased fish and determine the MIC value of sulfadiazine against Edwardsiella ictaluri by microdilution method; Step 2: A single oral administration was performed on healthy channel catfish at 18 ℃ and 24 ℃ respectively, and tissue samples were collected after administration; Step 3: administer a single intravenous dose to healthy channel catfish and collect tissue samples after administration; Step 4: respectively determining the residual amount of sulfadiazine in the tissue samples collected in step 2 and step 3; Step 5: Calculate pharmacokinetic parameters, including area under the concentration-time curve, absorption rate constant, elimination rate constant, and apparent distribution volume; Step 6: Determine the dosage regimen of sulfadiazine according to calculation formula 1; The calculation formula 1 is: ; In the calculation formula 1: Dose is the drug dose; Cmin is the steady-state concentration of sulfadiazine in fish, determined according to the MIC; Vd is the apparent volume of distribution; Ka is the absorption rate constant; K is the elimination rate constant; F is bioavailability; Δ is dosing interval; The calculation formula 2 of the bioavailability is: ; In the calculation formula 2: AUCoral The area under the curve for oral administration; AUCiv The area under the curve for intravenous administration of the drug; Doseiv For intravenous dose; Doseoral Oral dosage; In step 2 and step 3, the tissue samples are blood, muscle + skin, liver, kidney and gill.
2. The method for determining the dosing regimen of sulfadiazine in aquatic animals at different temperatures according to claim 1, characterized in that: In steps 2 and 3, the sampling time points were 0.083, 0.167, 0.5, 1, 2, 8, 16, 24, 48, and 72 h after administration.
3. The method for determining the dosing regimen of sulfadiazine in aquatic animals at different temperatures according to claim 1, characterized in that: In step 4, the residual amount of sulfadiazine is determined by high performance liquid chromatography.
